A new case study documents six months of complete pain relief in an 80-year-old man with arthritis, achieved without ...

Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...

Patients living with severe chronic pain don’t only have to manage a debilitating affliction. They also have to deal with the FDA making it harder for them to access potentially life-changing new ...

Compare Inpatient Rehab examined data from the CDC's National Health Interview Survey to examine the chronic pain epidemic.

While some pain may become more frequent as we age, it doesn’t mean we have to accept it as unavoidable or rely only on ...

Pain is personal and highly subjective. An event that causes excruciating intolerable agony for one person might be perceived by another as distressing but bearable. Even the same person may have a ...

Life with chronic pain is a tough road and affects millions worldwide. Chronic discomfort can interfere with every activity from daily activities to emotional well-being. But the good news is that ...

People with severe chronic pain were far more likely to have elevated levels of eosinophils, a type of white blood cell, a new study found, hinting at an immune link to pain – but the rise in these ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe ...